Innate Pharma DB:IDD 주식 보고서 Innate Pharma S.A.
DB:IDD 주식 보고서
IDD 주식 개요 생명공학 회사인 이네이트 파마는 프랑스 및 전 세계 암 환자를 위한 면역 치료제를 개발하는 기업입니다.
가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Innate Pharma 과거 주가 현재 주가 €1.60 52주 최고치 €2.70 52주 최저치 €1.58 베타 0.87 11개월 변경 -13.58% 3개월 변경 사항 -17.32% 1년 변경 사항 -27.58% 33년 변화 -64.13% 5년 변화 -70.62% IPO 이후 변화 -66.02%
최근 뉴스 및 업데이트 Innate Pharma SA Announces Board Changes Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH). Sep 26
First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023) Sep 18
New minor risk - Profitability Sep 13
New minor risk - Share price stability Jul 04 Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial Jun 18
더 많은 업데이트 보기 Innate Pharma SA Announces Board Changes Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH). Sep 26
First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023) Sep 18
New minor risk - Profitability Sep 13
New minor risk - Share price stability Jul 04 Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial Jun 18
New minor risk - Profitability Jun 05
No longer forecast to breakeven Jun 05
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides Jun 05
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients Apr 16
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate Apr 10
Forecast to breakeven in 2026 Mar 26
Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022) Mar 22
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma Mar 06 Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million. Feb 07
Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 Dec 11
Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023 Nov 03 Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024
New minor risk - Share price stability Oct 09
Innate Pharma S.A. Provides Update on Lacutamab Clinical Program Oct 05
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 Sep 22
First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022) Sep 17
Innate Pharma S.A. Announces Executive Changes Sep 15
Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Jul 12
Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Jul 11
Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer Jun 27
Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria Jun 17 Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress
Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies Jun 09 Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML May 27
No longer forecast to breakeven Mar 25
Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology Jan 16
Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022 Dec 11 Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023
Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides Sep 23
First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021) Sep 16
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study Aug 01
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer Jun 03 Innate Pharma S.A. Announces Supervisory Board Changes May 21
Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial Dec 16
Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort Dec 10
First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020) Sep 16
Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia Jul 07
Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides Jun 23
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting Jun 11
Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma Jun 10
Member of Supervisory Board Marcus Schindler has left the company Jun 05
Full year 2020 earnings released Apr 29
Full year 2020 earnings released Mar 19
Innate Pharma S.A. Advances Lacutamab Clinical Development Program Feb 09
Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development Jan 05
Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action Dec 17 Innate Pharma S.A., Annual General Meeting, May 28, 2021
Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome Nov 14 Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome
Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients Nov 06
New 90-day low: €3.01 Sep 27
New 90-day low - €3.59 Sep 10
First half earnings released Sep 09
New 90-day low - €5.11 Jul 30 주주 수익률 IDD DE Biotechs DE 마켓 7D -4.8% -2.2% 1.1% 1Y -27.6% -17.1% 13.5%
전체 주주 수익률 보기
수익률 대 산업: IDD 지난 1년 동안 -17.1 %를 반환한 German Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: IDD 지난 1년 동안 13.5 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is IDD's price volatile compared to industry and market? IDD volatility IDD Average Weekly Movement 4.4% Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: IDD 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: IDD 의 주간 변동성 ( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 생명공학 회사인 이네이트 파마는 프랑스 및 전 세계 암 환자를 위한 면역 치료제를 개발하는 기업입니다. 이 회사의 제품에는 피부 T세포 및 말초 T세포 림프종 치료 및 불응성 세자리 증후군 치료를 위한 임상 2상 시험 중인 항-KIR3DL2 항체 라쿠타맙(IPH4102), 대장암과 폐암, 두경부암을 포함하는 진행성 고형 종양 치료를 위한 임상 3상 시험 중인 면역 체크포인트 억제제 모날리주맙이 있습니다; CD39 면역 억제 경로를 표적으로 하는 임상 2상 시험 중인 차단 항체 IPH5201, 면역 억제 아데노신 경로를 표적으로 하여 항종양 면역을 촉진하는 항-CD73 항체 IPH5301; BCMA를 표적으로 하는 NK 세포 결합체 IPH6401, CD123을 표적으로 하는 NKp46 기반 NK 세포 결합체 IPH6101, 독점적인 다중 특이적 항체 형식, B7-H3를 표적으로 하는 NK 세포 결합체 IPH62. 전임상 시험 중인 제품으로는 항-MICA/B ADC인 IPH43과 항체 약물 접합체(ADC)인 IPH45, 그리고 아직 공개되지 않은 다중 특이적 ANKET인 IPH67이 있습니다.
자세히 보기 Innate Pharma S.A. 기본 사항 요약 Innate Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? IDD 기본 통계 시가총액 €134.22m 수익(TTM ) -€34.05m 수익(TTM ) €33.79m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) IDD 손익 계산서(TTM ) 수익 €33.79m 수익 비용 €53.65m 총 이익 -€19.86m 기타 비용 €14.20m 수익 -€34.05m
주당 순이익(EPS) -0.42 총 마진 -58.77% 순이익 마진 -100.78% 부채/자본 비율 121.3%
IDD 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}